Johnson & Johnson has announced the European launch of VARIPULSE Pro following CE Mark approval, marking the next evolution of its pulsed field ablation (PFA) portfolio.
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect.
VARIPULSE Pro introduces a new pulse sequence with a lower temperature profile and ablation speeds five times faster than the previous system, achieving equivalent lesions.
The platform integrates with the CARTO 3 System, featuring advanced mapping and tissue proximity indicators for precise lesion delivery. Early cases are being tracked under the VARIPURE multicenter, prospective postmarket study, with more clinical evidence planned during the commercial rollout.
“In our early experience, VARIPULSE Pro has been exceptionally smooth and easy to use,” said Tom De Potter, Head of Electrophysiology and Associate Director of the Heart Center, OLV Hospital, Aalst, Belgium.
“The speed is particularly striking and contributes to more efficient procedures without compromising precision. The integration with CARTO mapping and intracardiac echocardiography (ICE) facilitate accurate positioning and consistent lesion delivery, contributing to a very positive procedural experience.”
“The introduction of VARIPULSE Pro in Europe reflects our commitment to advancing our PFA platforms through continuous innovation, enhancing procedural experience while maintaining the consistency and precision physicians expect from the VARIPULSE Platform,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson.
“This launch demonstrates our dedication to continuously evolving PFA technologies based on real-world learnings and our scientific expertise, supporting physicians to deliver high-quality care and improved patient outcomes.”
